Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease

The European Journal of Neuroscience
D KirikA Björklund

Abstract

Here we studied the effects of glial cell line-derived neurotrophic factor (GDNF) in a rat model that represents the symptomatic stages of Parkinson's disease. GDNF was infused starting 2 weeks after an intrastriatal 6-hydroxydopamine (6-OHDA) lesion in order to halt the ongoing degeneration of the nigrostriatal dopaminergic neurons. GDNF or vehicle was infused in the striatum or the lateral ventricle via an osmotic minipump over a total 4-week period (2-6 weeks postlesion). Motor function was evaluated by the stepping, paw reaching and drug-induced motor asymmetry tests before the pump infusion was initiated, and was repeated once during (5 weeks postlesion) and twice after the withdrawal of the minipumps (7 and 11 weeks postlesion). We found that within two weeks following the lesion approximately 40% of the nigral TH-positive neurons were lost. In the vehicle infusion groups there was an additional 20% cell loss between 2 and 12 weeks after the lesion. This latter cell loss occurred mainly in the caudal part of the SN whereas the cell loss in the rostral SN was almost complete within the first two weeks. Ventricular GDNF infusion completely blocked the late degenerating neurons in the caudal SN and had long lasting behaviour...Continue Reading

References

Oct 1, 1991·Brain : a Journal of Neurology·J M Fearnley, A J Lees
Feb 1, 1991·Journal of Neuroscience Methods·C P MontoyaS B Dunnett
Sep 1, 1987·Journal of Microscopy·H J Gundersen, E B Jensen
May 15, 1995·The Journal of Comparative Neurology·K E BowenkampA C Granholm
Jun 1, 1994·Brain : a Journal of Neurology·M SchulzerD B Calne
May 30, 1998·Journal of Neuroscience Methods·T SaitoT Nemoto

❮ Previous
Next ❯

Citations

Mar 26, 2005·Brain Research. Molecular Brain Research·Juliann D Jaumotte, Michael J Zigmond
Apr 9, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Amie L Peterson, John G Nutt
Apr 7, 2005·Physiology & Behavior·Eddie CastañedaMichal K Stachowiak
Oct 20, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Sara E GombashCaryl E Sortwell
Feb 2, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Erik CederfjällTomas Björklund
Sep 1, 2009·Stem Cells and Development·Román VidaltamayoRené Drucker-Colin
Apr 6, 2005·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Yossef S LevyDaniel Offen
Jun 13, 2013·Brain : a Journal of Neurology·Maria XilouriLeonidas Stefanis
Mar 13, 2014·Drugs & Aging·Tiago Martins RodriguesMaria José Diógenes
Jul 4, 2012·Nutrition Reviews·Jianfei ChaoRaymond Chuen-Chung Chang
Dec 31, 2003·Experimental Neurology·Carrie B Hurelbrink, Roger A Barker
Mar 20, 2008·Expert Opinion on Therapeutic Targets·Jonathan R Evans, Roger A Barker
May 6, 2016·Neuromolecular Medicine·Liting HangKah-Leong Lim
Mar 15, 2006·International Journal of Pharmaceutics·N Popovic, P Brundin
Dec 14, 2005·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Diana ReimersEulalia Bazán
Feb 15, 2007·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Aijun ZhuAnna-Liisa Brownell
Oct 21, 2017·International Journal of Molecular Sciences·Napoleon TorresAlim Louis Benabid
Jan 30, 2004·Nature Neuroscience·Deniz KirikAnders Björklund
Jul 13, 2004·Annals of the New York Academy of Sciences·Soshana Behrstock, Clive N Svendsen
Mar 14, 2007·Current Opinion in Neurology·Monica Cardone
Nov 26, 2005·The European Journal of Neuroscience·Kuei Y TsengM Gustavo Murer
May 5, 2005·The European Journal of Neuroscience·Pedro Barroso-ChineaTomás González-Hernández
Jul 2, 2008·Expert Review of Neurotherapeutics·Murray HongIvar Mendez
Jan 1, 2014·The European Journal of Neuroscience·Simon R W Stott, Roger A Barker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Astrocytes in Parkinson Disease

Parkinson's disease (PD) is a neurodegenerative disorder caused by the progressive loss of dopaminergic neurons. Some PD-genes may be associated with astrocyte dysfunction. Discover the latest research on astrocytes in Parkinson's disease here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.